Akebia Therapeutics, Inc. (AKBA) analyst actions
Rating and price-target actions on AKBA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AKBA overview →
4 measured AKBA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases | Press release | -0.76% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akebia Therapeutics, Inc. (AKBA) And Encourages Shareholders to Reach Out | Press release | +0.00% | -0.27% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akebia Therapeutics, Inc. (AKBA) And Encourages Stockholders to Reach Out | Press release | +0.00% | -1.65% | |
| Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization | Press release | -1.47% | +0.54% |
Keep exploring
More AKBA: earnings → · SEC filings → · AKBA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Albireo Pharma, Inc. (ALBO) | 378 | +0.05% | 53% |
| REPRO MED SYSTEMS INC (REPR) | 378 | 0.00% | 26% |
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.